Madrigal Pharmaceuticals (MDGL)
(Delayed Data from NSDQ)
$245.49 USD
+9.33 (3.95%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $245.00 -0.49 (-0.20%) 5:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Madrigal Pharmaceuticals, Inc. [MDGL]
Reports for Purchase
Showing records 1 - 20 ( 184 total )
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rezdiffra Achieves Landmark Approval as the First Therapy Indicated for MASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
All Eyes on Resmetirom March 14 PDUFA; EMA Validates MAA; Significant Model Updates; Raise PT to $405
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Enter a New Key Challenger in the MASH Race: Sagimet''s Denifanstat Looks to Enter Phase 3 by YE24
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for MDGL 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q Recap; MAESTRO-NASH Results Prominently Featured in Presentations at AASLD; Increasing PT to $275; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Resmetirom''s NDA For NASH Fibrosis Under Priority Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
New CEO Takes the Reins, as the FDA''s Acceptance of the Resmetirom NDA, and Setting the PDUFA Date are Imminent
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Whole NASH Field Cheers as MAESTRO-NASH Is a Home Run; Raise PT to $225
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MAESTRO-NASH Outcomes NASH Cirrhosis Study Begins; Pivotal MAESTRO-NASH Top-line Results on Target in 4Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q Recap; Top-line Readout of Pivotal Phase 3 MAESTRONASH in 4Q Poised to Be a Watershed Event in NASH; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare Coverage Update - Dropping Coverage
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
4Q Recap: Our Positive Thesis Unfazed by Minor Delay in Pivotal Data Readout to 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Positive Results From MAESTRO-NAFLD-1 Tees Up a Low- Risk Pivotal Biopsy NASH Readout in 3Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
We See No Negative Read-Through From the Slight Delay of Top-Line Data From MAESTRO-NAFLD-1 to January 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Post-AASLD KOL Event Highlights Both Strong Non-Invasive Data and Increasing NIT Correlations to Histology Endpoints
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q21 Recap; Open-Label NAFLD Data Could Provide Early Read-Through By Year-End 2021; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q Recap: With Pivotal Readout in 3Q22, Resmetirom Poised to Become First-to-Market Therapy in NASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
MAESTRO-NASH''s Complete Enrollment Sets The Stage For Top-line Data Readout in 3Q22; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Madrigal Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q21 Recap; First 52-Week Data With Resmetirom in NAFLD Patients Expected at Major Conference in 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E